Kevin Shaw
General Counsel at NEXTCURE, INC.
Network origin in Kevin Shaw first degree
Entity | Entity type | Industry | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 15 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Kevin Shaw via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
GENVEC INC | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
NABRIVA THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
MACROGENICS, INC. | Pharmaceuticals: Major | Chief Operating Officer Corporate Officer/Principal | |
Yale University | College/University | Doctorate Degree Graduate Degree | |
GRITSTONE BIO, INC. | Biotechnology | Chairman Director/Board Member | |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Chief Administrative Officer Corporate Officer/Principal | |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
PIERIS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Chairman | |
University of California, Davis | College/University | Undergraduate Degree Doctorate Degree | |
INTERMUNE INC | Biotechnology | Director/Board Member | |
TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Chairman | |
Triplet Therapeutics, Inc.
Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Triplet Therapeutics, Inc. develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases. The company was founded by Jean-François Formela and Nessan Bermingham is headquartered in Cambridge, MA. | Medical/Nursing Services | Director/Board Member | |
CULLINAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
VACCINEX, INC. | Biotechnology | Director of Finance/CFO | |
ImVax, Inc.
ImVax, Inc. BiotechnologyHealth Technology ImVax, Inc. provides healthcare services. The company was founded in 2015 and is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member | |
Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD. | Pharmaceuticals: Major | Director of Finance/CFO | |
Drexel University | College/University | Undergraduate Degree | |
University of Illinois | College/University | Undergraduate Degree | |
ABBOTT LABORATORIES | Medical Specialties | Corporate Officer/Principal | |
HUMANIGEN, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Stritch School of Medicine | College/University | Doctorate Degree | |
JAZZ PHARMACEUTICALS PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Talon Therapeutics, Inc.
Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc. BiotechnologyHealth Technology NiKang Therapeutics, Inc. operates as biotechnology company. It focuses on developing novel small molecule oncology drug discovery. The company was founded by Zhenhai Gao and is headquartered in Wilmington, DE. | Biotechnology | Director/Board Member | |
Spark Therapeutics UK Ltd.
Spark Therapeutics UK Ltd. Medical/Nursing ServicesHealth Services Part of Roche Holding AG, Spark Therapeutics UK Ltd. is a healthcare services provider. The company is based in London, UK. Spark Therapeutics was founded in 2016. | Medical/Nursing Services | Director/Board Member | |
SPARK THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO | |
Broadpoint Securities, Inc.
Broadpoint Securities, Inc. Investment Banks/BrokersFinance Part of Gleacher & Co., Inc., Broadpoint Securities, Inc. is a company that provides broker-dealer and investment banking services. The company is based in New York, NY. Broadpoint Securities was acquired by BroadPoint Securities Group, Inc. on May 17, 2004 for $32 million. | Investment Banks/Brokers | Corporate Officer/Principal | |
Columbia College (New York) | College/University | Undergraduate Degree | |
Novartis Venture Fund
Novartis Venture Fund Investment ManagersFinance Novartis Venture Fund provides early stage venture capital to companies in Europe, North America and Asia. The fund's focus is on the development of novel therapeutics and platforms, therefore it focuses on such sectors as Biotechnology and Biopharma. The fund makes seed and early stage investments ranging up to USD 30 million per company over its life. The fund makes follow-on and co-investments. | Investment Managers | Director/Board Member | |
Myeloid Therapeutics, Inc.
Myeloid Therapeutics, Inc. BiotechnologyHealth Technology Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
IBERE PHARMACEUTICALS | Financial Conglomerates | Director/Board Member | |
SmithKline Beecham Pharmaceuticals Co.
SmithKline Beecham Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, SmithKline Beecham Pharmaceuticals Co. is a company that manufactures drugs and vaccines. The company is based in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Pittsburgh School of Medicine | College/University | Doctorate Degree | |
HBM HEALTHCARE INVESTMENTS AG | Investment Managers | Director/Board Member | |
Tufts University | College/University | Doctorate Degree | |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Graduate Degree | |
University of Maryland | College/University | Corporate Officer/Principal | |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | Biotechnology | Director/Board Member | |
SUTRO BIOPHARMA, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Dartmouth College | College/University | Undergraduate Degree | |
Adolor Corp.
Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Biotechnology | Director of Finance/CFO |
Statistics
International
United States | 43 |
Ireland | 3 |
Austria | 2 |
Germany | 2 |
United Kingdom | 2 |
Sectoral
Health Technology | 30 |
Consumer Services | 12 |
Finance | 8 |
Health Services | 3 |
Distribution Services | 2 |
Operational
Director/Board Member | 123 |
Independent Dir/Board Member | 44 |
Corporate Officer/Principal | 41 |
Chairman | 15 |
Undergraduate Degree | 12 |
Most connected contacts
Insiders | |
---|---|
Chau Khuong | 38 |
Elaine Jones | 37 |
David Kabakoff | 30 |
Stephen Webster | 23 |
Michael Richman | 16 |
Ellen Feigal | 16 |
Garry Nicholson | 14 |
Anne Borgman | 13 |
John Houston | 11 |
Solomon Langermann | 10 |
Han Myint | 5 |
Steven Cobourn | 4 |
Timothy Mayer | 4 |
Sebastien Maloveste | 4 |
Sourav Kundu | 2 |
- Stock Market
- Insiders
- Kevin Shaw
- Company connections